Cut upstream veterinary vaccine manufacturing costs by up to 89% per dose

▶

Click image above to see a taster video

Comparative process data show that an intensified fixed-bed bioreactor platform improves viral productivity and reduces upstream costs versus conventional adherent cell culture processes for veterinary vaccine manufacturing.

In our interactive summary and video, Dr Alex Chatel (Donaldson Company Inc. | Univercells Technologies) shows you how you can achieve:

✓

Up to +1.2 log

increase in viral titer versus flask, across multiple cell line/virus combinations

✓

Up to 74%

reduction in upstream COGS per dose versus stirred-tank bioreactors

✓

Up to 89%

reduction in upstream COGS per dose versus roller bottles

✓

>95%

cell viability and detachment at harvest, across multiple cell lines

Want to learn more?

View the interactive summary and video for free by clicking the link below.

✕

Please enter your email to access content Read now